FDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Market

Who cashes in: Vertex Pharmaceuticals VRTX and CRISPR Therapeutics CRSP co-own Casgevy and split economics on every treatment. Pediatric patients represent a meaningful expansion of the eligible population — sickle cell disease disproportionately affects children, and catching patients earlier in disease progression is the clinical and commercial argument for the label extension. At a list price north of $2 million per treatment, even a handful of additional annual patients moves the revenue needle for CRSP, which is the smaller and more leveraged of the two. VRTX is a larger company with a diversified pipeline, so the incremental impact is real but not transformational at the stock level. Bluebird Bio (BLUE) also has an approved gene therapy for sickle cell (Lyfgenia), and this approval puts more competitive pressure on its already-thin commercial ramp.

Who's exposed: Bluebird Bio (BLUE) is the most direct loser. Its Lyfgenia therapy competes in the same rare-disease space, and Casgevy's label now covers a younger population. Bluebird has struggled commercially and financially; a broader Casgevy label tightens the window for it to establish market share. Traditional standard-of-care players — hydroxyurea manufacturers and chronic transfusion programs — face long-term volume pressure as gene therapy access expands, though that shift plays out over years, not quarters.

What to watch next: The commercial tell is how many treatment centers are certified and staffed to handle pediatric gene therapy cases — the bottleneck has never been the label, it's been manufacturing slots and qualified sites. Watch VRTX and CRSP quarterly disclosures for the number of patients in the commercial funnel under age 12.